Anzeige
Mehr »
Login
Montag, 23.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PRLN | ISIN: US85205L1070 | Ticker-Symbol:
NASDAQ
23.12.24
15:30 Uhr
35,470 US-Dollar
-0,170
-0,48 %
1-Jahres-Chart
SPRINGWORKS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SPRINGWORKS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur SPRINGWORKS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.11.SpringWorks started at outperform by Evercore ahead of FDA decision3
13.11.SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark3
12.11.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights194- Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors...
► Artikel lesen
11.11.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical ...95- Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN - - Patients achieved deep and durable reductions...
► Artikel lesen
07.11.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors to be Presented at ...84- Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with...
► Artikel lesen
22.10.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 20241
SPRINGWORKS THERAPEUTICS Aktie jetzt für 0€ handeln
04.09.SpringWorks Therapeutics CEO sells over $1.9m in company stock3
04.09.JPMorgan raises SpringWorks stock price target, maintains overweight rating3
29.08.SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA1
29.08.SpringWorks shares hold buy rating as FDA accepts drug application1
28.08.FDA accepts SpringWorks application for mirdametinib for NF1-PN1
28.08.SpringWorks's NDA For Mirdametinib Granted Priority Review For Treatment Of NF1-PN1
28.08.SpringWorks Therapeutics, Inc.: FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN183- PDUFA target action date of February 28, 2025 - - EU Marketing Authorization Application also validated by European Medicines Agency - STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks...
► Artikel lesen
23.08.Here's Why You Should Invest in SpringWorks (SWTX) Stock Now2
21.08.SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating1
08.08.SpringWorks (SWTX) Q2 Earnings Beat, Ogsiveo Drives Revenues2
08.08.SpringWorks shares maintain Buy rating from H.C. Wainwright with raised target1
07.08.SpringWorks Therapeutics GAAP EPS of -$0.54 beats by $0.58, revenue of $59.73M beats by $25.15M1
07.08.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights174- Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter - - Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults...
► Artikel lesen
07.08.SpringWorks Therapeutics, Inc. - 8-K, Current Report1
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2